Review
doi: 10.1016/j.tibtech.2007.05.001.
Epub 2007 May 21.
Engineering antibodies for clinical applications
Affiliations
- PMID: 17512622
- DOI: 10.1016/j.tibtech.2007.05.001
Item in Clipboard
Review
Engineering antibodies for clinical applications
Trends Biotechnol.
2007 Jul.
Abstract
Molecular engineering has contributed immensely to the clinical success of antibodies in recent years. The modular structure of antibodies has permitted their modification in numerous ways, to meet various clinical requirements. With the help of antibody engineering, it has been possible to modify the molecular size, pharmacokinetics, immunogenicity, binding affinity, specificity and effector function of antibodies. In addition, fusion proteins of antibodies with various proteins and peptides have yielded targeted biological modifiers, toxins and imaging agents. This review focuses on the recent trends in antibody engineering for improving their clinical utility.
Similar articles
-
Antibody engineering and modification technologies.Biomol Eng. 2007 Jun;24(2):201-15. doi: 10.1016/j.bioeng.2007.03.004. Epub 2007 Mar 31. Biomol Eng. 2007. PMID: 17466589 Review.
-
Engineered antibodies take center stage.Hum Antibodies. 2001;10(3-4):127-42. Hum Antibodies. 2001. PMID: 11847424 Review.
-
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):640-56. doi: 10.1016/j.addr.2006.01.026. Epub 2006 May 23. Adv Drug Deliv Rev. 2006. PMID: 16904789 Review.
-
Engineered protein scaffolds as next-generation antibody therapeutics.Curr Opin Chem Biol. 2009 Jun;13(3):245-55. doi: 10.1016/j.cbpa.2009.04.627. Epub 2009 Jun 6. Curr Opin Chem Biol. 2009. PMID: 19501012 Review.
-
Antibodies and genetically engineered related molecules: production and purification.Biotechnol Prog. 2004 May-Jun;20(3):639-54. doi: 10.1021/bp030070k. Biotechnol Prog. 2004. PMID: 15176864 Review.
Cited by
-
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.Cancer Immunol Immunother. 2010 Nov;59(11):1665-74. doi: 10.1007/s00262-010-0892-3. Epub 2010 Jul 16. Cancer Immunol Immunother. 2010. PMID: 20635083 Free PMC article.
-
Engineering Antibodies for the Treatment of Infectious Diseases.Adv Exp Med Biol. 2017;1053:207-220. doi: 10.1007/978-3-319-72077-7_10. Adv Exp Med Biol. 2017. PMID: 29549641 Free PMC article. Review.
-
Modern Technologies for Creating Synthetic Antibodies for Clinical application.Acta Naturae. 2009 Apr;1(1):32-50. Acta Naturae. 2009. PMID: 22649585 Free PMC article.
-
Self-assembly of antibodies by chemical induction.Angew Chem Int Ed Engl. 2008;47(52):10179-82. doi: 10.1002/anie.200803507. Angew Chem Int Ed Engl. 2008. PMID: 19025747 Free PMC article. No abstract available.
-
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.J Nucl Med. 2009 Jul;50(7):1131-9. doi: 10.2967/jnumed.108.057695. Epub 2009 Jun 12. J Nucl Med. 2009. PMID: 19525458 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
